Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Antibiotic > Doxorubicin

Doxorubicin

Doxorubicin is a potent antineoplastic anthracycline antibiotic derived from the bacterium Streptomyces peucetius.
It intercalates with DNA and inhibits macromolecular biosynthesis, leading to cytotoxic effects in cancer cells.
Doxorubicin is widely used in the tretament of a variety of solid tumors and hematologic malignancies, but its clinical usefulness is limited by cardiotoxicity.
Reserach optimization of doxorubicin using advanced technologies like PubCompare.ai can enhance reproducibility, accuracy, and unlock new insights to improve its therapeutic efficacy and safety.

Most cited protocols related to «Doxorubicin»

1
Breast Cancer Gene Expression Profiling
Cited 31 times
Gene-expression data from 230 stage I to III breast cancers, without individual patient identifiers, were provided to the MAQC project by the University of Texas M.D. Anderson Cancer Center (MDACC) Breast Cancer Pharmacogenomic Program. Gene-expression results were generated from fine-needle aspiration specimens of newly diagnosed breast cancers before any therapy. The biopsy specimens were collected sequentially during a prospective pharmacogenomic marker discovery study approved by the institutional review board between 2000 and 2008. These specimens represent 70% to 90% pure neoplastic cells with minimal stromal contamination [12 (link)]. All patients signed informed consent for genomic analysis of their cancers. Patients received 6 months of preoperative (neoadjuvant) chemotherapy including paclitaxel, 5-fluorouracil, cyclophosphamide, and doxorubicin, followed by surgical resection of the cancer. Response to preoperative chemotherapy was categorized as a pathologic complete response (pCR = no residual invasive cancer in the breast or lymph nodes) or residual invasive cancer (RD). The prognostic value of pCR has been discussed extensively in the medical literature [13 (link)]. Genomic analyses of subsets of this sequentially accrued patient population were reported previously [9 (link),14 (link),15 (link)]. For each endpoint, we used the first 130 cases as a training set to develop prediction models, and the next 100 cases were set aside as independent validation set. Table 1 and Additional file 1 show patient and sample characteristics in the two data sets.
Popovici V., Chen W., Gallas B.G., Hatzis C., Shi W., Samuelson F.W., Nikolsky Y., Tsyganova M., Ishkin A., Nikolskaya T., Hess K.R., Valero V., Booser D., Delorenzi M., Hortobagyi G.N., Shi L., Symmans W.F, & Pusztai L. (2010). Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Research : BCR, 12(1), R5.
Full text: Click here
Publication 2010
Aspiration Biopsy, Fine-Needle Biopsy Breast Carcinoma Cells Cyclophosphamide Doxorubicin Ethics Committees, Research Fluorouracil Gene Expression Genome Malignant Neoplasm of Breast Malignant Neoplasms Neoadjuvant Chemotherapy Neoplasms Nodes, Lymph Operative Surgical Procedures Paclitaxel Patients Pharmacogenomic Analysis Pharmacotherapy Residual Cancer Therapeutics
2
Breast Cancer Tissue Sampling Study
Cited 26 times
Fresh frozen breast cancer tissue from every third patient diagnosed and treated between 1991 and 2004 at the Koo Foundation Sun-Yat-Sen Cancer Center (KFSYSCC) were randomly selected for the study. Patients with follow-up periods shorter than three years were excluded, with the exception of those who died of the disease within three years of the initial treatment. In cases of ineligibility, the following sample was selected. The selected tissue samples spanned the major transition periods of adjuvant chemotherapy from CMF (cyclophosphamide, methotrexate and fluorouracil) to CAF (cyclophosphamide, doxorubicin, fluorouracil) and to taxane-based regimens. Four hundred forty seven samples were obtained, but 135 samples were excluded due to insufficient RNA (n = 1), poor RNA quality (n = 116), or unacceptable microarray quality (n = 18). A total of 312 samples were eligible for the study (Cohort 1). Gene expression profiles of an additional 15 lobular breast carcinoma samples, collected between 1999 and 2004 and previously studied, were also included (Cohort 2). All patients were treated by a multidisciplinary team according to the guidelines consistent with the National Comprehensive Cancer Network [18 ]. Following modified radical mastectomy or breast-conserving surgery plus dissection of axillary nodes, patients received radiotherapy, adjuvant chemotherapy, and/or hormonal therapy, if indicated. Neoadjuvant chemotherapy was administered to patients with locally advanced disease. The study was approved by the institutional review board (ID number 20020128A) and ethical approval was obtained from the same board for samples without obtainable informed consent.
Kao K.J., Chang K.M., Hsu H.C, & Huang A.T. (2011). Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer, 11, 143.
Full text: Click here
Publication 2011
Axilla Breast-Conserving Surgery Carcinoma, Lobular Chemotherapy, Adjuvant Cyclophosphamide Dissection Doxorubicin Ethics Committees, Research Fluorouracil Freezing Malignant Neoplasm of Breast Malignant Neoplasms Methotrexate Microarray Analysis Modified Radical Mastectomy Neoadjuvant Chemotherapy Patients Radiotherapy taxane Therapeutics Tissues Treatment Protocols
3
Doxorubicin for Unresectable Hepatocellular Carcinoma
Cited 21 times
Patients aged >18 years with HCC unsuitable for resection or percutaneous ablation, (BCLC A/B, without portal invasion or extrahepatic spread) were eligible for the study. Eligibility criteria also included: no previous chemotherapy, radiotherapy or transarterial embolization (with or without chemotherapy), a confirmed diagnosis of HCC according to EASL, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and preserved liver function (Child-Pugh Class A or B). Patients were excluded if they had another primary tumor, advanced liver disease (bilirubin levels >3 mg/dl, AST or ALT >5 × upper limit of normal or >250 U/l), advanced tumoral disease (vascular invasion or extrahepatic spread, or diffuse HCC, defined as >50% liver involvement), or contraindications for doxorubicin administration.
All patients provided written informed consent. The study was performed in accordance with the Declaration of Helsinki, the International Conference on Harmonization Guideline on Good Clinical Practice, and relevant local laws and regulations. Ethics committee approval was obtained. Independent Data and Safety Monitoring Committees were established to monitor efficacy and safety data. The study was registered at www.clinicaltrials.gov (NCT00261378), conducted according to the HCC Clinical Trial Design guidelines [27 (link)], and reported according to CONSORT recommendations [28 (link), 29 (link)].
Lammer J., Malagari K., Vogl T., Pilleul F., Denys A., Watkinson A., Pitton M., Sergent G., Pfammatter T., Terraz S., Benhamou Y., Avajon Y., Gruenberger T., Pomoni M., Langenberger H., Schuchmann M., Dumortier J., Mueller C., Chevallier P, & Lencioni R. (2009). Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study. Cardiovascular and Interventional Radiology, 33(1), 41-52.
Publication 2009
Bilirubin Blood Vessel Child Clinical Trials Data Monitoring Committees Conferences Diagnosis Doxorubicin Eligibility Determination Embolization, Therapeutic Ethics Committees Liver Liver Diseases Neoplasms Patients Pharmacotherapy Radiotherapy Safety
4
Cytotoxicity Evaluation of Lapatinib
Cited 18 times
The MTT assay was used to access cytotoxicity (22 (link), 23 ). In detail, cells were grown in 96-well microtiter plates. To determine the toxicity of lapatinib, various concentrations of lapatinib diluted with medium were added into the wells. To test the effect of lapatinib on the chemosensitivity of cancer cells, lapatinib was added to the medium with various concentrations of doxorubicin in MCF-7, MCF-7/adr, MX or topotecan in S1 or S1-M1-80 cells, respectively, mitoxantrone and cisplatin in HEK293/pcDNA3.1, ABCG2-482-R5, ABCG2-482-G2, and ABCG2-482-T7 cells. The concentrations required to inhibit growth by 50% (IC50) were calculated from survival curves using the Bliss method (24 (link)). The degree of resistance was calculated by dividing the IC50 for the MDR cells by that of the parental sensitive cells. The degree of the reversal of MDR was calculated by dividing the IC50 for cells with the anticancer drug in the absence of lapatinib by that obtained in the presence of lapatinib.
Dai C.L., Tiwari A.K., Wu C.P., Su X.D., Wang S.R., Liu D.G., Ashby CR J.r., Huang Y., Robey R.W., Liang Y.J., Chen L.M., Shi C.J., Ambudkar S.V., Chen Z.S, & Fu L.W. (2008). Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2. Cancer research, 68(19), 7905-7914.
Publication 2008
Biological Assay Cardiac Arrest Cisplatin Cytotoxin Doxorubicin Lapatinib Malignant Neoplasms Mitoxantrone Parent Pharmaceutical Preparations Topotecan
5
Telomere Dynamics and Mitochondrial Function
Cited 16 times
Terc−/− and Tert−/−, p53−/− mice have been described previously15 (link),44 (link). Microarray analysis of HSCs, heart and liver tissues from WT, G1 and G4 Tert−/− and G2 Terc−/− mice was performed using either SAM (liver and heart) or fold change differences (HSCs) followed by Ingenuity pathway analysis (IPA). Quantitative RT–qPCR was analysed by ΔΔCt method. qPCR-based mitochondrial quantification was performed with two different primer sets for genomic and mitochondrial loci. Shock-frozen heart and liver tissues were used for ATP determination by HPLC. Mitochondrial oxygen consumption studies were performed in isolated heart and liver mitochondria using a XF24 extracellular flux analyser with substrates feeding electrons into complexes I, II and IV. Murine transthoracic echocardiography was conducted using a high-resolution micro ultrasound system as described previously45 (link). Competitive transplant experiments were performed following standard protocols. Fasting glucose concentrations were determined after 12–16 h of fasting. For in vivo Ad-Tert/PGC-1α transduction studies, mice were transduced with 109 virus particles per mouse and peripheral glucose levels determined 5–6 days post infection. Gluconeogenesis in isolated hepatocytes was determined following established protocols and glucose concentration is reported after protein standardization24 (link). For p53–ER activation studies in MEFs, control or experimental cells were either treated with ethanol vehicle or 4-OHT and mitochondrial mass was determined by MitoGreen and by qPCR. For promoter analysis, sequences of 2.8 kb (PGC-1α) and 2.6 kb (PGC-1β), upstream of the start sites, were amplified by PCR from genomic mouse heart DNA and cloned into a luciferase reporter vector. Upstream lengths were chosen based on potential p53 binding sites as identified by TRANSFAC. For chromatin immunoprecipitation, we followed the EZ-Chip protocol (Promega) using p53 specific antibody and control IgG. Doxorubicin was administered at 7.5 mg per kg body weight into 8-week-old mice and echocardiography was performed 7 days later. For full details, see Supplementary Methods.
Sahin E., Colla S., Liesa M., Moslehi J., Müller F.L., Guo M., Cooper M., Kotton D., Fabian A.J., Walkey C., Maser R.S., Tonon G., Foerster F., Xiong R., Wang Y.A., Shukla S.A., Jaskelioff M., Martin E.S., Heffernan T.P., Protopopov A., Ivanova E., Mahoney J.E., Kost-Alimova M., Perry S.R., Bronson R., Liao R., Mulligan R., Shirihai O.S., Chin L, & DePinho R.A. (2011). Telomere dysfunction induces metabolic and mitochondrial compromise. Nature, 470(7334), 359-365.
Publication 2011
afimoxifene Binding Sites Body Weight Cells Cloning Vectors DNA Chips Doxorubicin Echocardiography Electrons Ethanol Freezing Genome Gluconeogenesis Glucose Heart Hepatocyte High-Performance Liquid Chromatographies Immunoglobulins Immunoprecipitation, Chromatin Infection Liver Luciferases Microarray Analysis Mitochondria Mitochondria, Liver Mus NADH Dehydrogenase Complex 1 Oligonucleotide Primers Oxygen Consumption PPARGC1A protein, human Promega Proteins Shock, Cardiogenic Stem Cells, Hematopoietic telomerase RNA component TERT protein, human Tissues Transplantation Ultrasonography Virion

Most recents protocols related to «Doxorubicin»

1
Treatment of Pediatric Wilms Tumor
Not available on PMC !

Example 9

A pediatric patient with Stage IV Wilms tumor is treated with dactinomycin, doxorubicin, cyclophosphamide and vincristine for 65 weeks. Doses of the drugs are as follows: dactinomycin (15 mcg/kg/d [IV]), vincristine (1.5 mg/m 2 wk [IV)), Adriamycin (doxorubicin 20 mg/m2/d [IV]), and cyclophosphamide (10 mg/kg/d [IV]). Dactinomycin courses are given postoperatively and at 13, 26, 39, 52, and 65 weeks. Vincristine is given on days 1 and 8 of each Adriamycin course. Adriamycin is given for three daily doses at 6, 19, 32, 45, and 58 weeks. Cyclophosphamide is given for three daily doses during each Adriamycin and each dactinomycin course except the postoperative dactinomycin course. During each administration of dactinomycin and vincristine a dose of 0.2 cc/kg of DDFPe is administered while the patient breathes supplemental oxygen. *D'angio, Giulio J., et al. “Treatment of Wilms' tumor. Results of the third national Wilms' tumor study.” Cancer 64.2 (1989): 349-360.

US11857627B2. Fractionated radiotherapy and chemotherapy with an oxygen therapeutic (2024-01-02). NuvOx Pharma LLC [US]. Inventors: Evan C. Unger [US].
Full text: Click here
Patent 2024
Adriamycin Cyclophosphamide Dactinomycin Doxorubicin Malignant Neoplasms Nephroblastoma Oxygen Patients Pharmaceutical Preparations Pharmacotherapy Radiotherapy Vincristine
2
Anti-angiogenic Nanomedicine Delivery
Not available on PMC !

Example 2

Anti-angiogenesis treatment with integrin-targeted doxorubicin prodrug and paclitaxel prodrug PFC nanoparticles was demonstrated using an in vivo Matrigel plug model in rats. The therapeutic response was assessed using MRI neovascular mapping at 3 T with αvβ3 integrin-targeted paramagnetic PFC nanoparticles (FIG. 3). Angiogenesis was decreased by both treatment formulations relative to control. Similar results were obtained in vivo with the Vx2 tumor model in rabbits using paclitaxel prodrug (FIG. 4). Therefore, in contradistinction to prior research that showed loss of paclitaxel or doxorubicin during in vitro dissolution, the phospholipid prodrug forms were retained in circulation, delivered to the target cell, released enzymatically and exerted the intended antiproliferative effects.

US11872313B2. Prodrug compositions, prodrug nanoparticles, and methods of use thereof (2024-01-16). Washington University [US]. Inventors: Gregory M. Lanza [US], Dipanjan Pan [US].
Full text: Click here
Patent 2024
angiogen Cells Doxorubicin Integrins matrigel Neoplasms Oryctolagus cuniculus Paclitaxel Pathologic Neovascularization Phospholipids Prodrugs Rattus
3
AGuIX® Nanoparticles for Doxorubicin Delivery
Not available on PMC !

Example 3

50 μmol (Gd3+) of AGuIX® nanoparticles were redispersed in 125 μl of ultrapure water in order to obtain a solution at 400 mM ([Gd3+]). 2.85 mg of doxorubicin are placed in a 2.5 ml flask. 1.1 ml of ultrapure water are added to the flask, which is stirred until the doxorubicin has completely dissolved. A solution at 2.6 g/l of doxorubicin is then obtained, and is protected from the light with aluminium. 327 μl of this solution are then added to the solution of AGuIX®, as are 48 μl of ultrapure water. The flask is stirred for 30 minutes in the dark. A solution containing 100 mM of gadolinium and 170 mg/l of doxorubicin is thus obtained.

This solution is placed in a 3 kDa Vivaspin®, and a tangential filtration cycle is carried out in order to obtain a supernatant of 200 μl. The subnatant is analysed by UV-visible analysis. The supernatant is diluted 50-fold and is analysed by UV-visible analysis.

Example 4

A solution of doxorubicin at 170 mg/l is prepared according to the procedure described in Example 3, the solution of AGuIX® being replaced with ultrapure water.

US11857604B2. Nanovectors and uses (2024-01-02). NH THERAGUIX [FR], Universite Claude Bernard Lyon 1 [FR], Centre National de La Recherche Scientifique—CNRS— [FR]. Inventors: Olivier Tillement [FR], François Lux [FR], Fabien Rossetti [FR], Vu-Long Tran [VN], Clélia Mathieu [FR], Myleva Dahan [FR].
Full text: Click here
Patent 2024
AGuIX Aluminum Doxorubicin Filtration Gadolinium Light Suby's G solution
4
Regulation of Tumor-Suppressor Micropeptide by p53
Not available on PMC !

Example 11

As previously indicated, p53 is an important tumour suppressor. Given the potential role of micropeptide SEQ ID NO:3 in tumor suppression, the authors of the invention tested the potential regulation of SEQ ID NO:3 by stress and by p53 protein. The authors of the invention treated the isogenic cell lines HCT116 and HCT116 p53 knock-out with the p53 activator Nutlin3a (10 μM) and with the genotoxic chemotherapeutic agent Doxorubicin (1 μM). Interestingly, SEQ ID NO 3 was upregulated with genotoxic stress in HCT116, but the upregulation was impaired in HCT116 p53 KO (FIG. 25). These results suggest that SEQ ID NO:3 regulated by stress/damage in a p53-dependent manner and thereby, possibly downregulated in all cancers with mutational inactivation of p53. Therefore, its tumor suppressor activity can be related with p53 function, supporting the use of the micropeptide as a therapeutic agent in cancer.

US11858972B2. Micropeptides and uses thereof (2024-01-02). FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON [ES]. Inventors: Maria Abad Méndez [ES], Olga Boix Sánchez [ES], Emanuela Greco [ES], Iñaki Merino Valverde [ES].
Full text: Click here
Patent 2024
Cell Lines Doxorubicin Genotoxic Stress Malignant Neoplasms Mutation Neoplasms Pharmacotherapy Therapeutics Transcriptional Activation Tumor Suppressor Genes
5
PLGA-COOH Nanomedicine Synthesis Protocol
Terminal carboxyl poly (lactic-glycolic acid) copolymer PLGA-COOH was purchased from Ruixi Biotechnology Co., Ltd. (Xian, China). Perfluorobutane (PFP), doxorubicin (DOX), and poly (vinyl alcohol) (PVA, MW = 25,000) were purchased from Aladdin Co., Ltd. (Shanghai, China). Chloroform (CHCl3) and isopropyl alcohol were purchased from Sangon Biotech Co., Ltd. (Shanghai, China). MES buffer was purchased from Solarbio (Beijing, China). 1-Ethyl-3-(3-(dimethylamino)propyl) carbodiimide (EDC) and n-hydroxysuccinimide (sulfo-NHS) were purchased from Sigma (United States). Fluorescein isothiocyanate (FITC), 1,1-dioctadecyl-3,3,3,3-tetramethylindotricarbocyanine iodide (DiR) were purchased from Beyotime Biotechnology Ltd., Co. (Shanghai, China). The pUC57/m-Cherry and E. coli MG1655 (EcM) were purchased from Wuhan Miaoling Bioscience & Technology Co., Ltd. (Wuhan, China).
Du M., Wang T., Feng R., Zeng P, & Chen Z. (2023). Establishment of ultrasound-responsive SonoBacteriaBot for targeted drug delivery and controlled release. Frontiers in Bioengineering and Biotechnology, 11, 1144963.
Full text: Click here
Publication 2023
Buffers Carbodiimides Chloroform Doxorubicin Escherichia coli Fluorescein Glycols Iodides Isopropyl Alcohol Isothiocyanates N-hydroxysuccinimide N-hydroxysulfosuccimide perfluorobutane poly(lactic acid) Polylactic Acid-Polyglycolic Acid Copolymer Polyvinyl Alcohol Prunus cerasus

Top products related to «Doxorubicin»

1
Doxorubicin by Merck Group
Sourced in United States, Germany, United Kingdom, France, China, India, Italy, Poland, Macao, Japan, Sao Tome and Principe, Canada, Spain, Brazil, Australia, Belgium, Switzerland, Singapore, Israel
Doxorubicin is a cytotoxic medication that is commonly used in the treatment of various types of cancer. It functions as an anthracycline antibiotic, which works by interfering with the DNA replication process in cancer cells, leading to their destruction. Doxorubicin is widely used in the management of different malignancies, including leukemia, lymphoma, and solid tumors.
2
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
3
Dimethyl sulfoxide (dmso) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
4
Cisplatin by Merck Group
Sourced in United States, Germany, United Kingdom, China, Sao Tome and Principe, Macao, Italy, France, Canada, Japan, Spain, Czechia, Poland, Australia, India, Switzerland, Sweden, Belgium, Portugal
Cisplatin is a platinum-based medication used as a chemotherapeutic agent. It is a crystalline solid that can be dissolved in water or saline solution for administration. Cisplatin functions by interfering with DNA replication, leading to cell death in rapidly dividing cells.
5
Doxorubicin by Selleck Chemicals
Sourced in United States, China, Germany
Doxorubicin is a cytotoxic anthracycline antibiotic used as a chemotherapy medication. It functions by intercalating DNA and inhibiting the progression of the enzyme topoisomerase II, thereby disrupting DNA synthesis and inducing apoptosis in rapidly dividing cells.
6
Paclitaxel by Merck Group
Sourced in United States, Germany, United Kingdom, France, China, Macao, Japan, Sao Tome and Principe, Canada, Poland, Spain, Israel, Australia, Switzerland, Italy
Paclitaxel is a pharmaceutical compound used in the production of various cancer treatment medications. It functions as a microtubule-stabilizing agent, which plays a crucial role in the development and regulation of cells. Paclitaxel is a key ingredient in the manufacture of certain anti-cancer drugs.
7
Etoposide by Merck Group
Sourced in United States, Germany, United Kingdom, Japan, France, China, Italy, Canada, Switzerland, Belgium, Macao, Portugal, Poland
Etoposide is a chemotherapeutic agent used in the treatment of various types of cancer. It is a topoisomerase inhibitor that disrupts the process of DNA replication, leading to cell death. Etoposide is available as a solution for intravenous administration.
8
Methyl thiazolyl tetrazolium (mtt) by Merck Group
Sourced in United States, Germany, Italy, China, United Kingdom, Sao Tome and Principe, Macao, France, India, Switzerland, Japan, Poland, Spain, Belgium, Canada, Australia, Brazil, Ireland, Israel, Hungary, Austria, Singapore, Egypt, Czechia, Netherlands, Sweden, Finland, Saudi Arabia, Portugal
MTT is a colorimetric assay used to measure cell metabolic activity. It is a lab equipment product developed by Merck Group. MTT is a tetrazolium dye that is reduced by metabolically active cells, producing a colored formazan product that can be quantified spectrophotometrically.
9
Doxorubicin dox by Merck Group
Sourced in United States, Canada, Germany, Australia, Poland
Doxorubicin (DOX) is a chemotherapy medication used in the treatment of various types of cancer. It is a potent cytotoxic agent that works by interfering with the growth and division of cancer cells. Doxorubicin is a product of the Merck Group.
10
Penicillin streptomycin by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.

More about "Doxorubicin"

Doxorubicin, also known as DOX, is a potent antineoplastic anthracycline antibiotic that is derived from the bacterium Streptomyces peucetius.
This chemotherapeutic agent works by intercalating with DNA and inhibiting macromolecular biosynthesis, leading to cytotoxic effects in cancer cells.
Doxorubicin is widely used in the treatment of a variety of solid tumors and hematologic malignancies, such as breast cancer, leukemia, and lymphoma.
However, its clinical usefulness is limited by cardiotoxicity, a serious side effect that can lead to heart damage.
To optimize Doxorubicin research and enhance its therapeutic efficacy and safety, advanced technologies like PubCompare.ai can be utilized.
PubCompare.ai is an AI-powered platform that helps researchers locate the best protocols from literature, preprints, and patents through intelligent comparisons.
By using this tool, researchers can improve the reproducibility and accuracy of their Doxorubicin studies, unlocking new insights and potential applications.
When conducting Doxorubicin research, it is also important to consider related compounds and experimental procedures.
For instance, Cisplatin and Paclitaxel are other chemotherapeutic agents that are often used in combination with Doxorubicin.
Additionally, techniques like MTT assays, which measure cell viability, and the use of cell culture media containing FBS and Penicillin/Streptomycin, can be crucial for evaluating the efficacy and toxicity of Doxorubicin.
By leveraging these various tools and techniques, researchers can optimize their Doxorubicin research efforts and work towards improving the therapeutic outcomes for patients.